Aktienanalyse zu Alphatec Holdings, Inc. (ATEC)ATECAlphatec Holdings, Inc.

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.

3 analysts cover ATEC: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 24.33.